GEN-1 Immunotherapy for the Treatment of Ovarian Cancer

Thaker, Premal H.; Borys, Nicholas; Fewell, Jason G.; Anwer, Khursheed

doi:10.2217/fon-2018-0423

Cited by 13 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although chemotherapy is the established treatment for SOC, the survival rate remains low, and it is highly anticipated that new treatments will be successfully developed [9,10]. Therapies, such as targeted treatment and immunotherapy, are needed to combat this disease [11,12]. Recently, various of proteins have been found highly expressed in SOC tissues, some of which (including AIF1 and WNK1) have become potential therapeutic targets for SOC [13].…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Wang

Yue³

et al. 2019

J Ovarian Res

View full text Add to dashboard Cite

Ovarian cancer (OC) is a type of gynaecological malignancy with high mortality in females. Serous ovarian cancer (SOC) is a distinct subtype of OC with poor early diagnosis. Given the limitations of traditional therapies, such as chemotherapy, targeted treatment is therefore a promising therapy to improve the survival rate of SOC patients. Cyclophilin A (CYPA) is a member of Cyclophilin family and thought to participates in multiple cellular processes such as cell transduction and immune modulation. Recently, various of studies indicated that CYPA has critical impact on cancer progression. CYPA could regulate cell proliferation, invasion, and chemoresistance of multiple types of cancers. However, it is still unclear whether it could affect ovarian cancer. In this study, we demonstrated that CYPA was highly expressed in SOC tissues compared with adjacent tissues. Further, CYPA was significantly associated with clinical stage and lymphnode metastasis of SOC patients. Additionally, data indicated that knockdown of CYPA by its shRNA dramatically reduces migration and invasion capacity of SOC cells in vitro and blocks tumor metastasis in vivo. Our study investigates the involvement of CYPA in the progression and metastasis of SOC, and therefore provides CYPA as a promising therapeutic target for SOC treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Wang

Yue³

et al. 2019

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…It is worth mentioning that miR-3200 affects the transcriptional ability of several genes, such as, GEN1，TMTC4， TSC22D1， SGK1, ITGB5，SNX1, SUV39H1, CBX5,HOXA7, RAD54L.The study indicates that the immunotherapy based on GEN1 is good for ovarian cancer [ 17 ]. Moreover, the deletion of TMTC4 activates the unfolded protein [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

miR-3200 accelerates the growth of liver cancer cells by enhancing Rab7A

Song,

Xie,

Liu

et al. 2023

Non-coding RNA Research

View full text Add to dashboard Cite

“…GEN-1 was first investigated as an intraperitoneal injection and gained traction after a phase I study demonstrated that platinum-sensitive ovarian cancer patients derived an ORR of 50.0% (6/12) with a DCR of 91.7% (11/12) and good tolerability [ 329 ]. However, multiple phase I and II trials shortly followed involving platinum-resistant cohorts which failed to replicate these results [ 330 ]. Given the above, the focus has since shifted to applying GEN-1 as an adjunct to neoadjuvant chemotherapy for curative intent in ovarian cancer patients, as seen in the phase I OVATION-I trial which found an ORR of 85.7% (12/14) with CR in 14.3% (2/14) of patients and subsequent surgical resection of all macroscopic disease (R0) achieved in 64.3% (9/13) of participants [ 331 ].…”

Section: Targeting Strategies Against Myeloid Cells For Cancer Immuno...mentioning

confidence: 99%

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Wang

Johnson²,

Gatti‐Mays

et al. 2022

J Hematol Oncol

View full text Add to dashboard Cite

Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4 provide deep and durable treatment responses which have revolutionized oncology. However, despite over 40% of cancer patients being eligible to receive immunotherapy, only 12% of patients gain benefit. A key to understanding what differentiates treatment response from non-response is better defining the role of the innate immune system in anti-tumor immunity and immune tolerance. Teleologically, myeloid cells, including macrophages, dendritic cells, monocytes, and neutrophils, initiate a response to invading pathogens and tissue repair after pathogen clearance is successfully accomplished. However, in the tumor microenvironment (TME), these innate cells are hijacked by the tumor cells and are imprinted to furthering tumor propagation and dissemination. Major advancements have been made in the field, especially related to the heterogeneity of myeloid cells and their function in the TME at the single cell level, a topic that has been highlighted by several recent international meetings including the 2021 China Cancer Immunotherapy workshop in Beijing. Here, we provide an up-to-date summary of the mechanisms by which major myeloid cells in the TME facilitate immunosuppression, enable tumor growth, foster tumor plasticity, and confer therapeutic resistance. We discuss ongoing strategies targeting the myeloid compartment in the preclinical and clinical settings which include: (1) altering myeloid cell composition within the TME; (2) functional blockade of immune-suppressive myeloid cells; (3) reprogramming myeloid cells to acquire pro-inflammatory properties; (4) modulating myeloid cells via cytokines; (5) myeloid cell therapies; and (6) emerging targets such as Siglec-15, TREM2, MARCO, LILRB2, and CLEVER-1. There is a significant promise that myeloid cell-based immunotherapy will help advance immuno-oncology in years to come.

show abstract

GEN-1 Immunotherapy for the Treatment of Ovarian Cancer

Cited by 13 publications

References 48 publications

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

miR-3200 accelerates the growth of liver cancer cells by enhancing Rab7A

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Contact Info

Product

Resources

About